SCHEMBL4659260

SCHEMBL4659260

Nc1ccc2nc(N3CCOCC3)ccc2c1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ KMT2A Q03164 1/20 0.45
▸ ALDH1A1 P00352 7/20 0.45
▸ HPGD P15428 7/20 0.45
▸ GAA P10253 5/20 0.45
▸ KDM4E B2RXH2 5/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ HTR3A P46098 1/20 0.45
▸ CYP1A2 P05177 2/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ SMPD3 Q9NY59 1/20 0.44
▸ GLA P06280 2/20 0.43
▸ HSD17B10 Q99714 2/20 0.43
▸ HTT P42858 3/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ CASP1 P29466 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12701772 0.84 ALDH1A1 (0.56) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL1134096 0.83 NPC1 (0.48) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL12724325 0.80 ALDH1A1 (0.52) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL4779101 0.77 NPC1 (0.51) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL4658361 0.77 KDM4E (0.49) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL12701060 0.77 KDM4E (0.54) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL939415 0.75 SMPD3 (0.53) MEN1KMT2AALDH1A1HPGDGAA
SCHEMBL31570599 0.75 SMPD3 (0.53) MEN1KMT2AALDH1A1HPGDGAA
SCHEMBL4658327 0.75 ALDH1A1 (0.52) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL2411298 0.73 SMPD3 (0.51) MEN1KMT2AALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1819342-A4 QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2008-12-17 — — EP disclosed
US-20070293492-A1 Quinoline Tachykinin Receptor Antagonists MERCK SHARP & DOHME CORP. 2007-12-20 — — US disclosed
EP-1819342-A1 QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2007-08-22 — — EP disclosed
WO-2006060390-A1 QUINOLINE TACHYKININ RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2006-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293492-A1 Quinoline Tachykinin Receptor Antagonists TACR1, TACR2, NPSR1 NPC1 1917/4885RAB9A 3619/4885MEN1 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback